[Regulatory effect of FK506 on the expression of CD152 and PD-1 in the liver allo-recipients].
OBJECTIVE
To dynamically observe the expression of CTLA-4/CD152 and PD-1 on T cell surface in the peripheral blood of liver allo-recipients, and to explore the regulatory effect of FK506 on negative costimulatory molecules.


METHODS
The blood concentration of FK506 was measured by enzyme-multiplied immunoassay technique. Flow cytometry (FCM) was used to determine the expression of T cell subsets and CD152, PD-1 on T cell surface in the peripheral blood.


RESULTS
There was no significant difference in blood concentration of FK506 between each group (P > 0.05). With the progression of treatment, the frequency of CD4(+) T cells gradually decreased and was obviously lower than that in health control until the third month (P < 005). The expression of CD4(+) T cells in each treatment group was significantly lower than that in disease control group (P < 0.05). And the frequency of CD8(+) T cells in each treatment group was obviously higher than that in disease control group (P < 0.05). After liver transplantation, the expression of CD152 on CD4(+) and CD8(+) T cells was higher than that in health control group (P < 0.05), and the expression in the second week and first month was higher than that in disease control group (P < 0.05). The frequencies of CD4(+) CD152(+) T cells in the second and third month were lower than that in the second week and first month (P < 0.05). The frequency of CD8(+) CD152(+) T cells in the third month was lower than that in the second week and first month (P < 0.05). After liver transplantation, the expression of PD-1 on T cell subsets had the tendency of advancing. Its expression on CD4(+) T cells was significantly higher than that in health control group from the second week (P < 0.05), and the expression on CD8(+) T cells increased obviously from the first month compared with that in disease control group (P < 0.05).


CONCLUSIONS
FK506 could up-regulate the expression of negative costimulatory molecules CD152 and PD-1 on T cell surface and inhibit the proliferation and activation of effector T cells, which may contribute to maintain the survival and homeostasis of allo-recipients.
Li
Jia
J
Division of Clinical Immunological Laboratory, West China Hospital of Sichuan University, Chengdu 610041, China. polarbearli@163.com
Bai
Yang-juan
YJ
Wang
Lan-lan
LL
Wei
Hong-gang
HG
Cai
Bei
B
Yan
Lü-nan
LN
Wu
Hong
H
D015703:Antigens, CD / Q000235:genetics / Q000276:immunology*; D000943:Antigens, Differentiation / Q000235:genetics / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D060908:CTLA-4 Antigen; D049109:Cell Proliferation; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology*; D008099:Liver / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor; D013601:T-Lymphocytes; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D016559:Tacrolimus; D023001:Transplantation Tolerance / Q000276:immunology*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D053645:Interleukin-2 Receptor alpha Subunit; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; D007371:Interferon-gamma; D016559:Tacrolimus